나이 관련 황반변성
Background: Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries. Recently, AMD prevalence in Korea has increased from 6.6% to 13.9% over the past decade, which may be a threat to the public health of Korean society. This study describes the current status,...
Saved in:
| Published in | Taehan Ŭisa Hyŏphoe chi pp. 500 - 505 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Korean |
| Published |
대한의사협회
01.08.2024
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1975-8456 |
| DOI | 10.5124/jkma.2024.67.8.500 |
Cover
| Summary: | Background: Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries.
Recently, AMD prevalence in Korea has increased from 6.6% to 13.9% over the past decade, which may be a threat to the public health of Korean society. This study describes the current status, including risk factors, treatment, and economic burden of AMD in Korea.
Current Concepts: Major AMD risk factors have been consistently reported, including age, hypertension, smoking, and ultraviolet radiation. The primary AMD treatment is intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF). Anti-VEGF was developed and improved in terms of efficacy and safety. However, AMD treatment’s economic burden is significant. Therefore, several treatment strategies have been introduced, such as monthly, as-needed, and treat-and-extend injection strategies.
Discussion and Conclusion: With the rapid increase in AMD prevalence in Korea, the economic burden of AMD management will be a significant challenge for the Korean healthcare system. Therefore, cost-effectiveness and resource allocation for AMD treatment needs to be investigated. KCI Citation Count: 0 |
|---|---|
| ISSN: | 1975-8456 |
| DOI: | 10.5124/jkma.2024.67.8.500 |